New Delhi: IIT Bombay awarded 284 degrees during the interim session of its 60th annual convocation on Saturday. This was the first offline celebration at IIT Bombay involving degree holders, guests, and invitees since the initial Covid lockdown two years ago.
As per an institute statement, 284 degrees were awarded at the interim session of IIT Bombay's 60th convocation, including 189 PhDs and 20 Dual Degrees [10 (Mtech + PhD) and 10 (MSc + PhD)] to 209 students.
In addition, 68 students received 95 degrees, including 29 BTech, two BDes, one BS, 10 MTech, two MDes, two MPhil, six MSc, five MS by Research, seven PGDIIT, six DD (BTech + MTech), and five (E-MBA).
Dr Krishna M Ella, Chairman and Managing Director of Bharat Biotech and inventor of Covaxin, was the Chief Guest at the event, which was also attended by Dr Pawan Goenka, Chairman of the Board of Governors, IIT Bombay, and Professor Subhasis Chaudhuri, Director, IIT Bombay.
The degrees were granted to students who had fulfilled all of the prerequisites between August 2021 and January 2022 and had asked that the degree be offered before the 60th Convocation.
Subhasis Chaudhuri, director of IIT Bombay, congratulated the graduating students, saying, “This being the first fully physical event in the campus in the last two years, it was a delight to see the sea of joy among graduates and their relatives in the Convocation Hall.”
Krishna Ella emphasised the significance of creativity in the invention, urging the graduating class to pursue careers in science and technology that may be used in fields such as agriculture and healthcare.
Ella said, “One virus-genome destroyed the entire world’s economy. And this is going to be the reality. Earlier, people were scared of nuclear powers but it requires effort in transport and other aspects. But now one person with an infection is a bioweapon or biowarfare if you take it forward. The infectious disease now is not simply a healthcare issue but have become a national security issue. And just like nuclear, even vaccine science will be important for national security.”
Ella also emphasised the significance of clinical trials, pointing out that India has no tradition of clinical research.
Adding that his team is now working on developing a nasal vaccine for Covid, Ella said, “ You want vaccine research and innovation to be done. But nobody wants to participate in clinical trials. That is the sad part of this country”.
Also Read:
Comments